Simoa hd x platform

Manufactured by Quanterix

Sourced in United States

The Simoa HD-X platform is a highly sensitive and automated immunoassay system designed for the quantitative measurement of low-abundance proteins and other analytes in biological samples. The platform utilizes Simoa's proprietary digital detection technology to achieve unprecedented sensitivity and precision, enabling the detection and measurement of proteins at femtogram-per-milliliter levels.

Automatically generated - may contain errors

Lab products found in correlation

Lumipulse immunoassays, by Fujirebio (1 mentions) Neurology 2 plex b, by Quanterix (1 mentions) Neurology 3 plex a, by Quanterix (1 mentions) Simoa sr x platform, by Quanterix (1 mentions) Simoa nf light advantage kit, by Quanterix (1 mentions) Simoa gfap discovery kit, by Quanterix (1 mentions)

Close spelling variants of this product

Simoa platform (35 citations) Simoa HD-X (27 citations) HD-X platform (5 citations)

9 protocols using simoa hd x platform

Multimodal Biomarker Assessment of Alzheimer's

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Amyloid β plaque deposition was assessed using a [¹¹C] Pittsburgh Compound B (PiB) PET tracer. PET data were analyzed from a 30-minute acquisition window beginning 40 min after a bolus injection of approximately 15 mCi of PiB. All PiB PET scans were processed with the PET Unified Pipeline (PUP) [35 (link)], including conventional processing steps and partial volume correction with a regional spread function (RSF). Standardized uptake value ratios (SUVR) summarized PiB tracer binding in previously-defined summary regions, including bilateral precuneus, prefrontal cortex, gyrus rectus, and lateral temporal regions, using the cerebellum as a reference region [35 (link)].
Cerebrospinal fluid (CSF) samples were collected via lumbar puncture under fasting conditions [17 (link)]. CSF amyloid β42 (Aβ42), amyloid β40 (Aβ40), and phosphorylated tau-181 (pTau) were measured with Lumipulse immunoassays (Fujirebio). Aβ42 and pTau estimates were normalized for individual differences in CSF production rates by forming a ratio with Aβ40 as the denominator [36 (link), 37 ]. Neurofilament-light-chain (NfL) was measured with a Simoa HD-X platform (Quanterix).
Blood samples were collected via venipuncture under fasting conditions [38 (link)]. Plasma pTau and NfL were measured on a Simoa HD-X platform (Quanterix).

Millar P.R., Gordon B.A., Wisch J.K., Schultz S.A., Benzinger T.L., Cruchaga C., Hassenstab J.J., Ibanez L., Karch C., Llibre-Guerra J.J., Morris J.C., Perrin R.J., Supnet-Bell C., Xiong C., Allegri R.F., Berman S.B., Chhatwal J.P., Chrem Mendez P.A., Day G.S., Hofmann A., Ikeuchi T., Jucker M., Lee J.H., Levin J., Lopera F., Niimi Y., Sánchez-González V.J., Schofield P.R., Sosa-Ortiz A.L., Vöglein J., Bateman R.J., Ances B.M, & McDade E.M. (2023). Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease. Molecular Neurodegeneration, 18, 98.

+ Open protocol

+ Expand

Plasma Biomarker Quantification by Simoa

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood samples were collected in ethylene diamine tetraacetic acid (EDTA) plasma tubes and centrifuged (1000 rpm, 4°C) for 15 min. After the centrifugation, plasma was transferred into 1.5ml Eppendorf tubes and stored at −80 °C refrigerators.
Plasma Aβ_1-40, Aβ_1-42, t-tau, NfL, and p-tau181 were quantified using an ultra-sensitive single-molecule array (Simoa) (Quanterix, MA, USA) on the automated Simoa HD-X platform per the manufacturer’s instruction. The multiplex Neurology 3-Plex A kits (Cat. No. 101995), NF-light assay (Cat. No. 103186), and p-tau181 Assay Kit V2 (Cat. No.103714) were purchased from Quanterix and used accordingly. Technicians who performed the assay were blinded to the clinical data.

Xiao Z., Wu X., Wu W., Yi J., Liang X., Ding S., Zheng L., Luo J., Gu H., Zhao Q., Xu H, & Ding D. (2021). Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease. Alzheimer's Research & Therapy, 13, 123.

+ Open protocol

+ Expand

Plasma NfL and P-tau181 Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma NfL and P-tau181 were assayed in November and December of 2020 using ultra-sensitive Simoa technology on the automated Simoa HD-X platform (Quanterix, MA, USA). The P-tau181 V2 (Cat. No. 103714) and NfL (Cat No:103186) assay kits were procured from Quanterix and utilized in accordance with the manufacturer’s instructions. Plasma samples were diluted at a 1:4 ratio for all assays. All samples were analyzed using the same batch of kits. All the operators were blind to the participants’ cognitive diagnosis and clinical information.

Wu J., Xiao Z., Wang M., Wu W., Ma X., Liang X., Zheng L., Ding S., Luo J., Cao Y., Hong Z., Chen J., Zhao Q, & Ding D. (2024). The impact of kidney function on plasma neurofilament light and phospho-tau 181 in a community-based cohort: the Shanghai Aging Study. Alzheimer's Research & Therapy, 16, 32.

+ Open protocol

+ Expand

Plasma Tau Biomarkers Quantification

Cited 3 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma samples were collected according to standard procedures in the clinical routine. Samples were then rapidly frozen for permanent storage at −80°C.
²² (link) Plasma levels of pTau variants pTau‐181 and pTau‐231 were quantified using a custom Single molecule array (Simoa) assay as previously described.
²² (link) pTau‐217⁺ was quantified by Janssen R&D.
²³ (link) Plasma NTA‐tau concentrations were quantified using an in‐house–developed Simoa immunoassay using a Simoa HD‐X platform (Quanterix) at the Clinical Neurochemistry Laboratory (Mölndal, Sweden). Development and validation of the NTA assay has been previously described.
⁹ (link) In brief, plasma NTA assay is comprised by a mouse monoclonal antibody with epitope 6‐18aa (Tau12, BioLegend) used as a detector and a mouse monoclonal antibody with epitope 159‐163aa (HT7, Thermo Scientific) used as the capture antibody.

Woo M.S., Tissot C., Lantero‐Rodriguez J., Snellman A., Therriault J., Rahmouni N., Macedo A.C., Servaes S., Wang Y., Arias J.F., Hosseini S.A., Chamoun M., Lussier F.Z., Benedet A.L., Ashton N.J., Karikari T.K., Triana‐Baltzer G., Kolb H.C., Stevenson J., Mayer C., Kobayashi E., Massarweh G., Friese M.A., Pascoal T.A., Gauthier S., Zetterberg H., Blennow K, & Rosa‐Neto P. (2023). Plasma pTau‐217 and N‐terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid‐β positive individuals. Alzheimer's & Dementia, 20(2), 1166-1174.

+ Open protocol

+ Expand

CSF Biomarker Assays and AD Diagnosis

Check if the same lab product or an alternative is used in the 5 most similar protocols

We performed CSF biomarker assays using the Simoa SR-X platform^{1 (link),20 (link)} and plasma biomarker assays using the Simoa HD-X platform (both Quanterix). Samples were assayed in duplicate per the package insert instructions using the following Quanterix kits: Neurology 3-Plex A (catalog No. 101995) for Aβ42, Aβ40, and T-tau; pTau-181 V2 Advantage (catalog No. 103714) for P-tau181; and Neurology 2-Plex B (catalog No. 103520) for GFAP and NfL. Ratios of Aβ42/Aβ40, T-tau/Aβ42, and P-tau181/Aβ42 were calculated. Cerebrospinal fluid positivity for AD was determined using the CSF P-tau181/Aβ42 optimal cut point of 0.223 established in our laboratory. This CSF cut point is derived from receiver operating characteristic (ROC) analysis of a validation group of combined autopsy cases (n = 20) and amyloid PET cases (n = 59) with CSF biomarkers, including Aβ40, Aβ42, T-tau, P-tau181, and NfL (using Quanterix kit 103400), measured on the SR-X system. The area under the curve (AUC) was best for P-tau181/Aβ42, at 0.88 (0.79-0.97) with a Youden index of 0.82. At the P-tau181/Aβ42 cut point of 0.22, sensitivity was 0.95 and specificity was 0.87.

Honig L.S., Kang M.S., Lee A.J., Reyes-Dumeyer D., Piriz A., Soriano B., Franco Y., Coronado Z.D., Recio P., Mejía D.R., Medrano M., Lantigua R.A., Teich A.F., Dage J.L, & Mayeux R. (2023). Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity. JAMA Network Open, 6(4), e238214.

+ Open protocol

+ Expand

Plasma Biomarkers for Concussion Diagnosis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Five millilitres of blood was collected from each participant in plasma EDTA tubes. Samples were centrifuged at 2000g and plasma aliquoted and stored at −80° until assay. NfL, tau, GFAP and Aβ40 and Aβ42 were measured on the Simoa HD-X platform (Quanterix, Billerica, Massachusetts) according to the manufacturer’s instructions. Briefly, plasma samples were diluted fourfold and then incubated with paramagnetic beads coated with anti-Aβ40, anti-Aβ42, anti-GFAP, anti-NfL or anti-tau antibodies and biotinylated detector antibodies. Beads were washed and combined with a conjugate of streptavidin-b-galactosidase. This enzyme binds to biotinylated antibodies; bound enzyme is hydrolysed by resorufin-b-D-galactopyranoside producing a fluorescent signal that is read by the analyser. Calibrators run on the same assay produce a standard curve, enabling quantification of samples. All samples were analysed on one occasion using one batch of reagents; intra-assay coefficients of variation were below 10%. The number of results for each biomarker differs as a number of measurements can be lost due to technical issues or sample quality. In the control group, the number of measurable samples was tau (n=37), GFAP (n=38), NfL (n=38), Aβ40 (n=38) and Aβ42 (n=37). In the concussion group: tau (n=121), GFAP (n=119), NfL (n=119), Aβ40 (n=119) and Aβ42 (n=117).

Swann O.J., Turner M., Heslegrave A, & Zetterberg H. (2022). Fluid biomarkers and risk of neurodegenerative disease in retired athletes with multiple concussions: results from the International Concussion and Head Injury Research Foundation Brain health in Retired athletes Study of Ageing and Impact-Related Neurodegenerative Disease (ICHIRF-BRAIN study). BMJ Open Sport — Exercise Medicine, 8(3), e001327.

+ Open protocol

+ Expand

Ultrasensitive Plasma Biomarker Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols

All laboratory personnel were blinded to clinical information. To obtain plasma, venous blood samples collected in EDTA-containing tubes were centrifuged at 1800 rpm for 15 min at 4 °C. The supernatant was immediately removed, frozen in 200 μL aliquots, and stored at
-80 °C until further processing.
Plasma Aβ42, Aβ40, p-tau181, GFAP, and NfL levels were quantified using single molecule arrays (SiMoA), an ultra-sensitive enzyme-linked immunosorbent assay (ELISA) technique on an automated SiMoA HD-X platform (Quanterix, Billerica, MA, USA). The SiMoA Human Neurology 4-Plex E assay was used to measure GFAP, Aβ40, Aβ42, and NfL levels, whereas p-tau181 was quantified by the SiMoA p-tau181 Advantage V2 assay.

Wang J., Zhang Y.R., Shen X.N., Han J., Cui M., Tan L., Dong Q., Zubarev R.A, & Yu J.T. (2022). Deamidation-related blood biomarkers show promise for early diagnostics of neurodegeneration. Biomarker Research, 10, 91.

+ Open protocol

+ Expand

Biomarkers for Spinocerebellar Ataxia Diagnosis

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

All patients underwent a thorough neurological examination performed by at least two experienced neurologists. The overall disease severity was measured with the Scale for Assessment and Rating of Ataxia (SARA) for patients with familial and sporadic ataxia,¹³ (link) and with the Unified Multiple System Atrophy Rating Scale (UMSARS) for patients with MSA-c.¹⁴ (link) The Spinocerebellar Degeneration Functional Score (SDFS) scale was used to evaluate the functional disability of all patients.¹⁵ (link) Brain magnetic resonance imaging (MRI) data were collected on patients with GAA expansion when available. For patients carrying a GAA expansion in FGF14, plasma neurofilament light (pNfL) levels were measured with the single molecule array (Simoa) technique on the automated Simoa HD-X platform (Quanterix, MA), as described previously.¹⁶ (link)^,¹⁷ (link) These positive cases were classified as pre-ataxic stage with SARA < 3 and ataxic stage with SARA ≥ 3.¹⁸ (link)^,¹⁹ (link) In addition, 30 patients with SCA3 (including 15 pre-ataxic and 15 ataxic), 15 GAA-FGF14-negative patients with MSA-c, and 15 age-matched healthy individuals were enrolled as controls for pNfL testing.

Ouyang R., Wan L., Pellerin D., Long Z., Hu J., Jiang Q., Wang C., Peng L., Peng H., He L., Qiu R., Wang J., Guo J., Shen L., Brais B., Danzi M.C., Zuchner S., Tang B., Chen Z, & Jiang H. (2024). The genetic landscape and phenotypic spectrum of GAA-FGF14 ataxia in China: a large cohort study. eBioMedicine, 102, 105077.

+ Open protocol

+ Expand

Simultaneous Measurement of NfL and GFAP

Check if the same lab product or an alternative is used in the 5 most similar protocols

NfL and GFAP were measured simultaneously with all individuals randomized across the included assays using the same reagent batch of SIMOA NF-Light Advantage kit and SIMOA GFAP Discovery Kit, respectively, on the Simoa HD-X platform (Quanterix Corp). Detailed descriptions of the protocol for analytical measurements, interassay and intra-assay variability, calibration limits, and data on the number of samples analyzed are described in the eAppendix in the Supplement.

Sjöbom U., Hellström W., Löfqvist C., Nilsson A.K., Holmström G., Pupp I.H., Ley D., Blennow K., Zetterberg H., Sävman K, & Hellström A. (2021). Analysis of Brain Injury Biomarker Neurofilament Light and Neurodevelopmental Outcomes and Retinopathy of Prematurity Among Preterm Infants. JAMA Network Open, 4(4), e214138.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!